Clinical impact of molecular identification of rare yeasts and nonsporulating molds recovered in culture from clinical specimens

Jean, Sophonie; Lainhart, William; Anderson, Neil W.; Yarbrough, Melanie L.; Burnham, Carey Ann D.

doi:10.1016/j.diagmicrobio.2019.114945

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…211 Currently, fungal DNA sequencing is considered the gold standard for reliable identification of most rare yeasts. 5,152,169,212,213 Genus-specific antifungal drug profiles can be observed but species-level susceptibility profiles are often variable. 5,172,197 Local antifungal prophylactic strategies may increase the risk of nosocomial rare yeast infections by exerting excessive selective pressure.…”

Section: Recommendationsmentioning

confidence: 99%

Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology/oncology setting, 2021

Hall

Cooper

Grigoriadis

et al. 2021

Internal Medicine Journal

View full text Add to dashboard Cite

Cryptococcosis caused by the Cryptococcus neoformans-Cryptococcus gattii complex is an important opportunistic infection in people with immunodeficiency, including in the haematology/oncology setting. This may manifest clinically as cryptococcal meningitis or pulmonary cryptococcosis, or be detected incidentally by cryptococcal antigenemia, a positive sputum culture or radiological imaging. Non-Candida, non-Cryptococcus spp. rare yeast fungaemia are increasingly common in this population. These consensus guidelines aim to provide clinicians working in the Australian and New Zealand haematology/oncology setting with clear guiding principles and practical recommendations for the management of cryptococcosis, while also highlighting important and emerging rare yeast infections and their recommended management.

show abstract